新利司他, 胃脂肪酶抑制剂

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
C153471-1g
1g 现货 Stock Image
C153471-5g
5g 现货 Stock Image
C153471-25g
25g 现货 Stock Image
C153471-100g
100g 现货 Stock Image
查看相关系列
pancreatic lipase Inhibitor (2)

基本描述

别名 2-十六烷氧基-6-甲基-4H-3,1-苯并恶嗪-4-酮 | 西替利斯他 | 赛利司他 | 西替利斯塔
英文别名 SCHEMBL367612 | AMY25231 | Betahistine mesilate (JP17) | Cetilistat [INN] | F16711 | ATL962 | ATL-962 | Cametor | CETILISTAT [JAN] | MK-212-HCL | N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid | UNII-LC5G1JUA39 | AKOS025248278 | CCG-26
规格或纯度 Moligand™, ≥98%(HPLC)
英文名称 Cetilistat
运输条件 常规运输
作用类型 抑制剂
作用机制 胃脂肪酶抑制剂
产品介绍

Cetilistat (ATL-962) 是一种胰腺脂肪酶 (pancreatic lipase) 抑制剂,可作为有效的抗肥胖药。Cetilistat 抑制大鼠和人胰脂肪酶活性,IC50 分别为 54.8 nM 和 5.95 nM。

Product Describtion:

Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively.

AI解读

产品属性

ALogP 9.8

关联靶点(人)

PNLIP Tclin 胰腺三酰甘油脂肪酶(Pancreatic triacylglycerol lipase) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)

关联靶点(其它种属)

Hdac6 Histone deacetylase 6 (222 活性数据)
活性类型 Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
rep Replicase polyprotein 1ab (378 活性数据)
活性类型 Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SARS-CoV-2 (38078 活性数据)
活性类型 Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

PubChem SID 488196466
分子类型 小分子
IUPAC Name 2-hexadecoxy-6-methyl-3,1-benzoxazin-4-one
INCHI InChI=1S/C25H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-28-25-26-23-18-17-21(2)20-22(23)24(27)29-25/h17-18,20H,3-16,19H2,1-2H3
InChi Key MVCQKIKWYUURMU-UHFFFAOYSA-N
Canonical SMILES CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1
Isomeric SMILES CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1
PubChem CID 9952916
分子量 401.59
Reaxy-Rn 14110675

化学和物理性质

溶解性 Insoluble in DMSO; ≥4.12 mg/mL in EtOH (Need ultrasonic and warming); insoluble in H2O
熔点 72.0 ~76.0 °C
分子量 401.600 g/mol
XLogP3 9.800
氢键供体数Hydrogen Bond Donor Count 0
氢键受体数Hydrogen Bond Acceptor Count 4
可旋转键计数Rotatable Bond Count 16
精确质量Exact Mass 401.293 Da
单同位素质量Monoisotopic Mass 401.293 Da
拓扑极表面积Topological Polar Surface Area 47.900 Ų
重原子数Heavy Atom Count 29
形式电荷Formal Charge 0
复杂度Complexity 477.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 0
未定义的原子立体中心计数Undefined Atom Stereocenter Count 0
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 1

安全和危险性(GHS)

Reaxy-Rn 14110675

技术规格说明书

Purity(HPLC) 98-100(%)
Melting point 72-76(℃)
Appearance(C153471) White to Off-White Solid, Powder, or Crystals
Proton NMR spectrum Conforms to Structure

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到6个结果

批号(Lot Number) 证书类型 日期 货号
D1728021 分析证书 25-01-17 C153471
B2207308 分析证书 22-01-04 C153471
B2207309 分析证书 22-01-04 C153471
B2207310 分析证书 22-01-04 C153471
C2330738 分析证书 22-01-04 C153471
F2307046 分析证书 22-01-04 C153471

此产品的引用文献

1. Jinpeng Liu, Mashooq Khan, Yong Wei, Anna Liu, Tao Wang, Qiongzheng Hu, Li Yu.  (2023)  High-throughput screening of lipase inhibitors as anti-obesity drugs on liquid crystal-infused porous surfaces.  SENSORS AND ACTUATORS B-CHEMICAL,  387  (133837).  [10.1016/j.snb.2023.133837]
2. Wenzhe Ji, Dingqiang Lu, Shaoning Yang, Tongqi Liu, Xinxian Wang, Xiuquan Ling.  (2016)  Solubility and solution thermodynamics of cetilistat in water and (acetone, isopropyl alcohol, acetonitrile) binary solvent mixtures.  JOURNAL OF MOLECULAR LIQUIDS,  224  (1380).  [10.1016/j.molliq.2016.10.127]

参考文献

1. Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P.  (2007)  Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients..  Int J Obes (Lond.),  31  (3): (494-9).  [PMID:16953261] [10.1021/op500134e]
2. Gras J.  (2013)  Cetilistat for the treatment of obesity..  Drugs Today (Barc),  49  (12): (755-9).  [PMID:24524093] [10.1021/op500134e]
3. Yuan S, Chan JFW, Chik KKH, Chan CCY, Tsang JOL, Liang R, Cao J, Tang K, Chen LL, Wen K et al..  (2020)  Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system..  Pharmacol Res,  159  (13): (104960).  [PMID:32473310] [10.1021/op500134e]
4. Jinpeng Liu, Mashooq Khan, Yong Wei, Anna Liu, Tao Wang, Qiongzheng Hu, Li Yu.  (2023)  High-throughput screening of lipase inhibitors as anti-obesity drugs on liquid crystal-infused porous surfaces.  SENSORS AND ACTUATORS B-CHEMICAL,  387  (133837).  [10.1016/j.snb.2023.133837]
5. Wenzhe Ji, Dingqiang Lu, Shaoning Yang, Tongqi Liu, Xinxian Wang, Xiuquan Ling.  (2016)  Solubility and solution thermodynamics of cetilistat in water and (acetone, isopropyl alcohol, acetonitrile) binary solvent mixtures.  JOURNAL OF MOLECULAR LIQUIDS,  224  (1380).  [10.1016/j.molliq.2016.10.127]

溶液计算器